Tag: MDC

Medlab Clinical ASX 2021 H2 H1 NanaBis NanoCBD

Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1

Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue from Special Access Scheme (SAS) sales of its NanaBis an...
Medlab ASX MDC Arrotex Australia Group NanoCBD TGA

Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies

Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-track availability of its proprietary cannabinoid formulat...
Medlab Clinical MDC ASX NRGBiotic Phase IIa Depression trial

Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms

Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic has revealed a “significant” reduction in depression. The trial involved administering NRGBiotic to ...
Medlab Clinical ASX MDC NanaBis non-opioid pain treatment phase three cancer NanoCelle

Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials

Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outperforms opioids for cancer-related pain management, should...
Medlab Clinical ASX MDC NanaBis FDA new drug status IND approval

Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis

Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lead candidate NanaBis, which is designed for treating canc...
TGA cannabis changes pot stocks Therapeutic Goods Administration cannabidiol CBD over-the-counter OTC

Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that ...
Medlab Clinical NanaBis ASX MDC cancer trial results Royal North Shore Hospital

Medlab’s NanaBis spray deemed safe for chronic pain management in patients with advanced breast and prostate cancers

Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel drug candidate to be safe, tolerable and fast-acting with...
Medlab Clinical ASX MDC trial Nanostat spray improved metabolic functioning tablet version atorvastatin

Medlab trial shows Nanostat spray delivers improved metabolic functioning over tablet version

Australian-based Medlab Clinical (ASX: MDC) has reported results of a bioequivalence trial involving an orobuccal spray version of its Nanostat cardiovascular medication which have indicated improved ...
Medlab Clinical ASX MDC cannabis export licence

Export licence granted to Medlab in development of cannabis pain management products

Australian life sciences company Medlab Clinical (ASX: MDC) has been granted a licence to export cannabis relating to the development of its NanaBis and NanaBidial cancer pain management medications. ...
Medlab Clinical ASX MDC positive feedback doctors prescribing cannabis cancer pain

Medlab Clinical gets positive feedback from doctors prescribing cannabis for cancer pain

Medlab Clinical (ASX: MDC) has claimed it has received positive feedback from doctors prescribing its cannabis-based medicine NanaBis for the pain management of cancer patients. The Australian medi...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS